

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Jean-Marc BALLOUL et al.)	Group Art Unit: 1648
Application No.: 09/506,942)	Examiner: S. Foley
Filed: February 18, 2000)	
For: PHARMACEUTICAL COMPOSITION)	
FOR TREATING PAPILLOMAVIRUS)	
TUMORS AND INFECTION)	

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☒ Charge \$ 180.00 to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$ _____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: March 12, 2001

By: *Teresa Stanek Rea*
Teresa Stanek Rea
Registration No. 30,427

Reg. No.
40,323

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Jean-Marc BALLOUL et al.)	Group Art Unit: 1648
)	
Application No.: 09/506,942)	Examiner: S. Foley
)	
Filed: February 18, 2000)	
)	
For: PHARMACEUTICAL COMPOSITION)	
FOR TREATING PAPILLOMAVIRUS)	
TUMORS AND INFECTION)	
)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of the document cited is enclosed.

U.S. PATENT DOCUMENTS

U.S. Patent No. 6,096,869 to Stanley et al., issued August 1, 2000.

The following documents were submitted in parent application, U.S. Patent Application Serial No. 09/043,933, and are therefore not enclosed.

U.S. PATENT DOCUMENTS

U.S. Patent No. 5,618,536 to Lowy et al., issued April 8, 1997 and;

U.S. Patent No. 5,855,891 to Lowy et al., issued June 5, 1999.

FOREIGN PATENT DOCUMENTS

WO 96/29091, September 1996;

WO 94/24267, October 27, 1994;

WO 93/00436;
WO 94/23037;
WO 93/02184;
WO 90/10459;
WO 96/00583;
WO 96/29091;
WO 96/11274;

OTHER DOCUMENTS

Zhou et al., Virology, 185:241-257;
Heck et al., PNAS USA, 89:4442-4446;
Galloway, 1994, "Human Papillomavirus Vaccines: A Warty Problem", Infectious Agents and Disease, 3:187-193;
Hines et al., 1995, "Prospects for a Vaccine against Human Papillomavirus", Obstetrics and Gynecology, 86(5):860-866;
Gajewski, 1996, "B7.1 but not B7.2 Efficiently Costimulates CD8+ T Lymphocytes in the P815 Tumor System *in vitro*", The Journal of Immunology, 156:465-472;
Crook et al., "Degradation of P53 can be Targeted by HPV E6 Sequences Distinct from those Required for P53 Binding and Transactivation", 67:547-556;
Munger et al., 1989, "Complex Formation of Human Papillomavirus E7 Proteins with the Retinoblastoma Tumor Suppressor Gene Product", The EMBO Journal, 8:4099-4105;
and
International Search Report dated November 19, 1997.


A fee in the amount of \$180.00 (126) is enclosed in conformance with 37 C.F.R. § 1.97(c).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:


Teresa Stanek Rea
Registration No. 30,427

Reg. No.
40,323

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: March 12, 2001